Results 51 to 60 of about 17,376 (176)
Clinical Case Reports, Volume 14, Issue 7, July 2026.ABSTRACT Methotrexate (MTX) is primarily renally excreted, making patients with end‐stage renal disease (ESRD) highly vulnerable to drug accumulation and toxicity. While severe drug‐induced hypersensitivity syndrome (DIHS) is a known life‐threatening adverse reaction, its association with acute central nervous system complications, specifically ...
Le Mu +6 more
wiley +1 more source
Case Reports in Medicine, 2012 Patients with autosomal dominant polycystic kidney disease become symptomatic and are diagnosed usually at adulthood. The rate of nephrolithiasis in these patients is 5–10 times the rate in the general population, and both anatomic and metabolic ...
Fatih Firinci +4 more
doaj +1 more source
Autosomal dominant polycystic kidney disease in Toronto
Kidney International, 1993 This study describes the Toronto, Ontario experience with autosomal dominant polycystic kidney disease (ADPKD). Patients were divided into three groups: Group 1, 19 families studied with genetic markers; Group 2, 80 pre-dialysis ADPKD patients followed by Toronto nephrologists in whom the incidence of non-renal complications and the mean age of onset ...
Roscoe, Janet M. +4 more
openaire +2 more sources
Angiogenesis in autosomal-dominant polycystic kidney disease [PDF]
Kidney International, 2001 Autosomal-dominant polycystic kidney disease (ADPKD) is a genetic disorder that is responsible for approximately 10% of all cases of end-stage renal disease (ESRD). It is characterized by the formation of epithelial cell cysts, an increase in the extracellullar matrix, and vascular alterations believed to be the result of compression by the cysts.
Bello-Reuss, Elsa +2 more
openaire +2 more sources
Design of Nanocarriers for Kidney Targeted Delivery of Nucleic Acid Therapeutics
Macromolecular Bioscience, Volume 26, Issue 7, July 2026.Nucleic acid therapeutics have been investigated to expand their applications to renal genetic disorders. This review summarizes key considerations in the design and fabrication of nanocarriers for the systemic delivery of nucleic acid therapeutics to the kidneys.
Jun Hyuk Lee +3 more
wiley +1 more source
Autosomal dominant polycystic kidney disease in children [PDF]
Current Opinion in Pediatrics, 2015 Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disease, affecting one in 500 individuals. The cardinal manifestation of ADPKD is progressive cystic dilatation of renal tubules with kidney enlargement and progression to end-stage renal disease in approximately half of cases by 60 years of age.
openaire +2 more sources
Knowledge Mapping of Alport Syndrome: A Bibliometric Analysis From 2000 to 2025
Molecular Genetics &Genomic Medicine, Volume 14, Issue 7, July 2026.This bibliometric analysis outlines global research trends, collaborations, and hotspots of Alport syndrome, offering references for future basic research and clinical management. ABSTRACT Background Alport syndrome (AS) is a multisystem hereditary disorder characterized by persistent hematuria, progressive renal insufficiency, sensorineural hearing ...
Xiujuan Cao +4 more
wiley +1 more source
Medical Journal of Australia, Volume 224, Issue 7, July 2026.ABSTRACT We report a case of a kidney transplant recipient who presented with generalised muscle pain, weakness and brown urine discoloration in the setting of acute severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Investigations demonstrated rhabdomyolysis with elevated creatine kinase levels and severe acute kidney injury (AKI).
Navya Kataria +8 more
wiley +1 more source
Fetal polycystic kidney disease: Pathological overview
Journal of the Scientific Society, 2013 Polycystic kidney disease is a rare developmental anomaly inherited as autosomal dominant or autosomal recessive. It is characterized by cystic dilatation of the collecting ducts frequently associated with hepatic involvement and progression to renal ...
Sunita B Patil +3 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra +4 more
wiley +1 more source